IP Library › Granted Patent US 12,622,956
Granted Patent B2
US 12,622,956 · App. 17/822,051 · Granted May 12, 2026

Methods and vaccines for inducing immune responses to multiple different MHC molecules

Inventors: Dustin B. McCurry (Phoenix, AZ); Peter A. Cohen (Scottsdale, AZ); Latha B. Pathangey (Scottsdale, AZ); Sandra J. Gendler (Scottsdale, AZ); Mary L Disis (Renton, WA)
Assignees: Mayo Foundation for Medical Education and Research;; University of Washington
A61K39/00117A61K39/0011A61K39/001106A61K39/001114A61K39/001168A61K39/001184A61K39/12A61K39/245A61K39/39A61K40/11A61K40/4205A61K40/4257A61K40/46A61P35/02C07K14/005C07K16/00A61K2039/55505A61K2039/55511A61K2039/55561A61K2039/55566A61K2039/55572A61K2239/49C12N2710/16122C12N2710/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,622,956
App. No.
17/822,051
Granted
May 12, 2026
Kind
B2
Abstract

This document provides methods and materials relating to isolated polypeptides, polypeptide preparations, vaccine preparations (e.g., anti-cancer vaccine preparations), and methods for vaccinating mammals. For example, polypeptides (e.g., CMV, MUC1, HER2, Mesothelin (MESO), TRAG-3, or CALR polypeptides) having the ability to be processed into different polypeptides such that the processed polypeptides as a group are capable of being presented by different MHC molecules present in a particular mammalian population are provided.

Claims (32)

1 . An isolated polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said polypeptide is amidated at the C-terminus.

2 . An isolated polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said polypeptide is acetylated at the N-terminus.

3 . A composition comprising at least one isolated polypeptide and an adjuvant, wherein the amino acid sequence of said at least one polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, MF59, Pam3CSK4, LPS, polyIC, imiquimod, or R848.

4 . The composition of claim 3 , wherein said polypeptide is amidated at the C-terminus and/or acetylated at the N-terminus.

5 . The composition of claim 3 , wherein said adjuvant is aluminum sulfate or aluminum phosphate.

6 . A method of treating cancer or a precancerous condition in a mammal, wherein said method comprises administering to said mammal a composition comprising an adjuvant and at least one polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, or MF59.

7 . The method of claim 6 , wherein said mammal is a human.

8 . The method of claim 6 , wherein said method comprises treating said cancer, and wherein said cancer is breast cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, colon cancer, multiple myeloma, leukemia, brain cancer, or melanoma cancer.

9 . The method of claim 6 , wherein said method comprises treating said precancerous condition, and wherein said precancerous condition is primary myelofibrosis, essential thrombocythemia, or polycythemia vera.

10 . The method of claim 6 , wherein said adjuvant is aluminum sulfate or aluminum phosphate.

11 . The method of claim 6 , wherein said polypeptide is amidated at the C-terminus and/or acetylated at the N-terminus.

12 . A vaccine comprising an adjuvant and at least one polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, or MF59.

13 . The vaccine of claim 12 , wherein said adjuvant is CpG or MF59.

14 . The vaccine of claim 12 , wherein said polypeptide is amidated at the C-terminus and/or acetylated at the N-terminus.

15 . A method of inducing an immune response against at least one polypeptide, wherein the sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, wherein said method comprises administering a composition comprising said polypeptide and an adjuvant to a mammal in an amount effective to induce an immune response against said polypeptide, wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, or MF59.

16 . The method of claim 15 , wherein said adjuvant is aluminum sulfate or aluminum phosphate.

17 . The method of claim 15 , wherein said adjuvant is CpG or MF59.

18 . The method of claim 15 , wherein said polypeptide is amidated at the C-terminus and/or acetylated at the N-terminus.

19 . A method of treating cancer or a precancerous condition in a mammal, wherein said method comprises contacting T-cells obtained from said mammal with at least one polypeptide set forth in any one of SEQ ID NOs:1-58 to activate said T-cells, and administering said activated T-cells to said mammal.

20 . The method of claim 19 , wherein said mammal is a human.

21 . The method of claim 19 , wherein said method comprises treating cancer, and wherein said administering reduces the number of cancer cells within said mammal.

22 . The method of claim 21 , wherein said cancer is breast cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, colon cancer, multiple myeloma, leukemia, brain cancer, or melanoma cancer.

23 . The method of claim 19 , wherein said method comprises treating said precancerous condition, and wherein said administering reduces a symptom of said precancerous condition within said mammal.

24 . The method of claim 23 wherein said precancerous condition is primary myelofibrosis, essential thrombocythemia, or polycythemia vera.

25 . The method of claim 19 , further comprising expanding said activated T-cells prior to administering said activated T-cells to said mammal.

26 . A method of treating cancer or a precancerous condition in a mammal, wherein said method comprises administering activated T-cells to said mammal, wherein said activated T-cells are T-cells that were obtained from said mammal and contacted with at least one polypeptide to activate said T-cells, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58.

27 . The method of claim 26 , wherein said mammal is a human.

28 . The method of claim 26 , wherein said method comprises treating cancer, and wherein said administering reduces the number of cancer cells within said mammal.

29 . The method of claim 28 , wherein said cancer is breast cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, colon cancer, multiple myeloma, leukemia, brain cancer, or melanoma cancer.

30 . The method of claim 26 , wherein said method comprises treating said precancerous condition, and wherein said administering reduces a symptom of said precancerous condition within said mammal.

31 . The method of claim 30 wherein said precancerous condition is primary myelofibrosis, essential thrombocythemia, or polycythemia vera.

32 . The method of claim 26 , wherein said activated T-cells were expanded prior to being administering to said mammal.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 9, 2023
From: MAYO CLINIC ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062320/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: DISIS, MARY L.
To: UNIVERSITY OF WASHINGTON
Reel/Frame 061224/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: MCCURRY, DUSTIN B.; COHEN, PETER A.; PATHANGEY, LATHA B.; GENDLER, SANDRA J.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 061224/0541 →
Continuity (3)
Continuation 15781393
Provisional Application 62263256 · Dec 4, 2015
Related Publication 20230098624A1 · Mar 30, 2023
References Cited (115)
US 6548643B1 · McKenzie et al. · 2003 [cited by applicant]
US 6734172B2 · Scholler et al. · 2004 [cited by applicant]
US 7202346B2 · Payne et al. · 2007 [cited by applicant]
US 7524503B2 · Khanna et al. · 2009 [cited by applicant]
US 7659117B2 · Laus et al. · 2010 [cited by applicant]
US 7820786B2 · Thomson et al. · 2010 [cited by applicant]
US 7935804B2 · Dubensky, Jr. et al. · 2011 [cited by applicant]
US 8815249B2 · Humphreys et al. · 2014 [cited by applicant]
US 8951526B2 · Yonezawa · 2015 [cited by applicant]
US 11464839B2 · McCurry et al. · 2022 [cited by applicant]
US 20040101534A1 · Diamond · 2004 [cited by applicant]
US 20090274714A1 · Singh · 2009 [cited by examiner]
US 20120308513A1 · Wollan et al. · 2012 [cited by applicant]
US 20130011424A1 · Maksyutov et al. · 2013 [cited by applicant]
US 20130011426A1 · Tureci et al. · 2013 [cited by applicant]
US 20130028915A1 · Palucka et al. · 2013 [cited by applicant]
US 20130108657A1 · Yee et al. · 2013 [cited by applicant]
US 20130203163A1 · Wollan et al. · 2013 [cited by applicant]
US 20140286858A1 · Zimmerman et al. · 2014 [cited by applicant]
US 20140356318A1 · Barken · 2014 [cited by examiner]
US 20150196628A1 · Mason et al. · 2015 [cited by applicant]
US 20190000948A1 · McCurry et al. · 2019 [cited by applicant]
WO WO2001074855 · 2001 [cited by applicant]
WO WO2001082963 · 2001 [cited by applicant]
WO WO2005049072 · 2005 [cited by applicant]
WO WO2006056027 · 2006 [cited by applicant]
WO WO2009059011 · 2009 [cited by applicant]
WO WO2009155535 · 2009 [cited by applicant]
WO WO2011110953 · 2011 [cited by applicant]
WO WO2012038055 · 2012 [cited by applicant]
WO WO2013025972 · 2013 [cited by applicant]
WO WO2015033140 · 2015 [cited by applicant]
WO WO2015100360 · 2015 [cited by applicant]
WO WO2015157189 · 2015 [cited by examiner]
WO WO2017034833 · 2017 [cited by applicant]
Nielsen et al (PLoS Computational Biology, 2008, vol. 4, No. 7, e1000107, 10 pages) (Year: 2008). [cited by examiner]
Abstract of Rughetti et al.(Blood, 2008, vol. 112, p. 5237) (Year: 2008). [cited by applicant]
Ackerman et al., “A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells,” Immunity, Oct. 2006, 25(4):607-617. [cited by applicant]
Ackerman et al., “Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens,” Proc. Natl. Acad. Sci. USA, Oct. 28, 2003, 100(22):12889-12894. [cited by applicant]
Akiyama et al., “Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus,” Immunol. Lett., Aug. 2002, 83(1):21-30. [cited by applicant]
Alves et al., “Differential regulation of human IL-7 receptor alpha expression by IL-7 and TCR signaling,” J. Immunology, Apr. 15, 2008, 180(8):5201-5210. [cited by applicant]
Apostolopoulos et al., “A glycopeptide in complex with MHC class I uses the GaINAc residue as an anchor,” Proc. Natl. Acad. Sci. USA, Dec. 1, 2003, 100(25):15029-15034. [cited by applicant]
Arentz-Hansen et al., “Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues,” Gastroenterology, Sep. 2002, 123(3):803- 809. [cited by applicant]
Belizaire et al., “Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation,” Proc. Natl. Acad. Sci. USA, Oct. 13, 2009, 106(41):17463-17468. [cited by applicant]
Belyakov et al., “Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge,” Proc. Natl.… [cited by applicant]
Brinckerhoff et al., “Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines,” Int. J. Cancer, Oct. 1999, 83(3):326-34. [cited by applicant]
Caserta et al., “IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells,” Eur. J. Immunology, Feb. 2010, 40(2):470-479. [cited by applicant]
Chhabra et al., The Scientific World Journal, 2011, vol. 11, pp. 121-129 (Year: 2011). [cited by applicant]
Cieri et al., “IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors,” Blood, Jan. 24, 2013, 121(4):573-584. [cited by applicant]
Cohen et al., “CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection,” Crit. Rev. Immunology, 2000, 20(1):17-56. [cited by applicant]
Cohen et al., “STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells,” Blood, Sep. 1, 2008, 112(5):1832-1843. [cited by applicant]
Cohen et al., “T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance,” Crit. Rev. Immunology, 2001, 21(1-3):215-248. [cited by applicant]
Crespo et al., “TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8alpha+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell sur… [cited by applicant]
Delamarre et al., “Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation,” J. Exp. Medicine, Jul. 7,… [cited by applicant]
Deshpande et al., “IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens,” J. Immunology, Feb. 15, 2013, 190(4):1416-1423. [cited by applicant]
Di Genova et al., “Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid,” Eur. J. Immunology, Apr. 2010, 40(4):976-985. [cited by applicant]
Disis et al., “Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer,” J. Clin. Oncology, 27(28): 4685-4692. [cited by applicant]
Disis et al., “Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines,” J. Clin. Oncology, Jun. 1, 2002, 20(11):2624-2632. [cited by applicant]
Disis et al., “HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers,” Cancer Immunol. Immunotherapy, Feb. 2014, 63(2):101-109. [cited by applicant]
Dudley et al., “Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma,” J. Clin. Oncology, Apr. 1, 2005, 23(10):234… [cited by applicant]
Dudley et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, Oct. 25, 2002, 298(5594):850-854. [cited by applicant]
Dudley et al., “Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma,” J. Clin. Oncology, Jun. 10, 2013, 31(17)… [cited by applicant]
European Search Report in European Application No. 16871630.6 dated Jul. 16, 2019, 16 pages. [cited by applicant]
European Search Report in European Application No. 16871630.6 dated Oct. 28, 2019, 10 pages. [cited by applicant]
Faure et al., “Long-lasting cross-presentation of tumor antigen in human DC,” Eur. J. Immunology, Feb. 2009, 39(2):380-390. [cited by applicant]
Fraser et al., “Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates,” Vaccine, May 19, 2014, 32(24):2896-2903. [cited by applicant]
Gagnon et al., “Increased antigen responsiveness of naive CD8 T cells exposed to IL-7 and IL-21 is associated with decreased CD5 expression,” Immunol. Cell Biology, May-Jun. 2010, 88(4):451-460. [cited by applicant]
Garulli et al., “Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo,” Clin. Vaccine Immunology, Oct. 2008, 15(10):1497-1504. [cited by applicant]
Gragert et al., “Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry,” Hum. Immunology, Oct. 2013, 74(10):1313-1320. [cited by applicant]
Hattrup et al., “Structure and function of the cell surface (tethered) mucins,” Annu. Rev. Physiology, 2008, 70:431-457. [cited by applicant]
Hertz et al., “HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1,” PLoS Pathogens, Jun. 20, 2013, 9(6):e1003404, 14 pages. [cited by applicant]
Heukamp et al., “Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice,” Int. J. Cancer, Feb. 2001, 91(3):385-392. [cited by applicant]
Imai et al., “Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells,” Int. Immunology, Jan. 2005, 17(1):45-53. [cited by applicant]
Jackson et al., “A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses” Proc. Natl. Acad. Sci. U.S.A., Oct. 2004, 101(4… [cited by applicant]
Kaech et al., “Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells,” Nat. Immunology, Dec. 2003, 4(12):1191-1198. [cited by applicant]
Karosiene et al., “NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ,” Immunogenetics, Oct. 2013, 65(10):711-724. [cited by applicant]
Karyampudi et al., “A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102,” Clin. Cancer Research, Feb. 1, 2010, 16(3):825-834. [cited by applicant]
Katz et al., “T cell receptor stimulation impairs IL-7 receptor signaling by inducing expression of the microRNA miR-17 to target Janus kinase 1,” Sci. Signaling, Aug. 26, 2014, 7(340):ra83, 10 pages. [cited by applicant]
Kisselev et al., “Proteasome inhibitors: from research tools to drug candidates,” Chem. Biology, Aug. 2001, 8(8):739-758. [cited by applicant]
Knutson et al., “IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion,” Clin. Exp. Immunology, Feb. 2004, 135(2):322-329. [cited by applicant]
Knutson et al., “Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients,” J. Clin. Investigation, Feb. 2001, 107(4):477-484. [cited by applicant]
Kobayashi et al., “Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen,” Cancer Research, Sep. 15, 2000, 60(18):5228-5236. [cited by applicant]
Koenen et al., “Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals,” Nat. Communications, Apr. 16, 2013, 4:1735, 10 pages. [cited by applicant]
Kovjazin et al., “ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors,” Vaccine, Jun. 24, 2011, 29(29-30):4676-4686. [cited by applicant]
Kreer et al., “Cross-presentation: how to get there—or how to get the Erm” Front. Immunology, Jan. 3, 2012, 2:87, 10 pages. [cited by applicant]
Kruit et al., “Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in M… [cited by applicant]
Lu et al., “Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions,” Clin. Cancer Research, Jul. 1, 2014, 20(13):3401-3410. [cited by applicant]
Madan et al., “Clinical evaluation of TRICOM vector therapeutic cancer vaccines,” Semin. Oncology, Jun. 2012, 39(3):296-304. [cited by applicant]
Markley et al., “IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice,” Blood, Apr. 29, 2010, 115(17):3508-3519. [cited by applicant]
McKinstry et al., “Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2,” Nat. Communications, Nov. 5, 2014, 5:5377, 12 pages. [cited by applicant]
Melief et al., “Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines,” Nat. Rev. Cancer, May 2008, 8(5):351-360. [cited by applicant]
Men et al., “MHC class I- and class II-restricted processing and presentation of microencapsulated antigens,” Vaccine, Mar. 5, 1999, 17(9-10):1047-1056. [cited by applicant]
Ménager et al., “Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1,” PLoS One, Feb. 27, 2014, 9(2):e89897, 13 pages. [cited by applicant]
Morgan et al., “High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens,” J… [cited by applicant]
Nielsen et al., “NetMHCIIpan-2.0—Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure,” Immunome Res., Nov. 2010, 6:9. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2016/064749, dated Jun. 5, 2018, 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2016/064749, dated Apr. 28, 2017, 13 pages. [cited by applicant]
Peng et al., “Helper-independent, L-selectin(low) CD8(+) T cells with broad anti- tumor efficacy are naturally sensitized during tumor progression,” J. Immunology, Nov. 15, 2000, 165(10):5738-5749. [cited by applicant]
Quoix et al., “Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial,” Lancet Oncology, Nov. 2011, 12(12):1125-1133. [cited by applicant]
Rongcun et al., “Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas,” J. Immunology, Jul. 15, 1999, 163(2):1037-1044. [cited by applicant]
Rosalia et al., “Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation,” Eur. J. Immunology, Oct. 2013, 43(10):2554-2565. [cited by applicant]
Sabbatini et al., “Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients,” Clin. Cancer Research, Dec. 1, 2012,… [cited by applicant]
Salazar et al., “Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine,” J. Clin. Oncology, May 20, 2009, 27(15_suppl):3010, 4 pages. [cited by applicant]
Sinnathamby et al., “Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification,” J. Immunology, Apr. 1, 2003, 170(7):3504-3513. [cited by applicant]
Slingluff Jr. et al., “A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602),” Clin. Cancer Research, Aug. … [cited by applicant]
Slingluff Jr. et al., “Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting,” Clin. Cancer Research, Nov. 1, 2007, 13(21):6386-6395. [cited by applicant]
Surman et al., “Localization of CD41 T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing,” Proc. Natl. Acad. Sci. USA, Apr. 10, 2011, 98(8):4587-4… [cited by applicant]
Tewari et al., “A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent,” Nat. Immunology, Mar. 2005, 6(3):287-294. [cited by applicant]
Tran et al., “Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer,” Science, May 9, 2014, 344(6184):641-645. [cited by applicant]
Wang et al., “Adoptive transfer of tumor-primed, in vitro-activated, CD4(+) T effector cells (T(E)s) combined with CD8(+) T(E)s provides intratumoral T-E proliferation and synergistic antitumor response,” Blood, Jun. 1,… [cited by applicant]
Wang et al., “CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells,” Clin. Cancer Res., Jul. 2015, 21(13):2993-3002. [cited by applicant]
Zehner et al., “The translocon protein sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells,” Immunity, May 19, 2015, 42(5):850-863. [cited by applicant]
Zeng et al., “Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function,” J. Exp. Medicine, Jan. 3, 2005, 201(1):139-148. [cited by applicant]
Zhang et al., “Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells,” J. Biol. Chemistry, Apr. 3, 2009, 284(14):9184-9191. [cited by applicant]
Zhang et al., “Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes,” BMC Bioinformatics, 2008, 9(Suppl 1):S19, 9 pages. [cited by applicant]